Time to treatment as a quality metric in lung cancer: Staging studies, time to treatment, and patient survival
Time to treatment as a quality metric in lung cancer: Staging studies, time to treatment, and patient survival
复制标题
DOI：
10.1016/j.radonc.2015.04.010
复制
发表时间：
2015-05-01
影响因子：
5.7
通讯作者：
Smith, Benjamin D.
中科院分区：
文献类型：
--
作者：
Gomez, Daniel R.;Liao, Kai-Ping;Smith, Benjamin D.
目的：及时的分期和治疗是非小细胞肺癌（NSCLC）的关键。我们确定诊断后治疗延迟的预测因素是否与预后相关。材料和方法：2004-2007年诊断为NSCLC的28，732例患者的医疗保险索赔用于建立诊断至治疗间隔（理想情况下，
Purpose: Prompt staging and treatment are crucial for non-small cell lung cancer (NSCLC). We determined if predictors of treatment delay after diagnosis were associated with prognosis.Materials and methods: Medicare claims from 28,732 patients diagnosed with NSCLC in 2004-2007 were used to establish the diagnosis-to-treatment interval (ideally,